Stockreport

BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch [Seeking Alpha]

BioAtla, Inc.  (BCAB) 
PDF Jay Short, Co-Founder, CEO & Chairman, emphasized that BioAtla is "currently in advanced stages to finalize a strategic transaction with a potential partner by year-end [Read more]